Insider and congress filings

Hims & Hers Health, Inc. (HIMS)

NYSE · Healthcare · 355 insider transactions · 2 congress trades · last filed 11 days ago

14
Open-market insider filings shown
1d
Median delay on the insider filings, in business days
within the two business day rule
0 buys·14 sells
Purchases and sales in the filings shown
Get a push when an insider at Hims & Hers Health, Inc. trades.

Free on iOS and Android.

About Hims & Hers Health, Inc.

from the company's filings and listing, as of Oct 23, 2026
Exchange
NYSE
Sector
Healthcare
Industry
Medical - Care Facilities
Chief executive
Andrew Dudum
Employees
2,442
Listed since
-
Market value
$6.6B
Price to earnings (12 mo)
-
Net income per share, as reported (12 mo)
-$0.61
Dividend yield
-

www.hims.com

Company news

1 article · newest first
HeadlineSourceDate
Hims & Hers Health launches injectable and oral testosterone therapiesThe treatments are for eligible men with low testosterone and are offered with licensed providers through Hims.Company releaseOct 21, 2026

Written by GetSignal with AI from the company's own SEC filings and press releases; each article links to its source. Not investment advice. Company news from every company we cover

Earnings

6 reported quarters · next on Nov 9, 2026
QuarterEPSEPS expectedRevenueRevenue expectedResult
Q2 FY2026reported Aug 10, 2026-$0.37-$0.05$753.2M$698.9MEPS miss, GAAPRevenue beat
Q1 FY2026reported May 11, 2026-$0.40$0.03$608.1M$616.8MEPS miss, GAAPRevenue in line
Q4 FY2025reported Feb 23, 2026$0.07$0.02$617.8M$619.2MEPS beatRevenue in line
Q3 FY2025reported Nov 3, 2025$0.06$0.09$599.0M$618.1MEPS miss, GAAPRevenue miss
Q2 FY2025reported Aug 4, 2025$0.17$0.18$544.8M$584.1MEPS miss, GAAPRevenue miss
Q1 FY2025reported May 5, 2025$0.20$0.12$586.0M$538.6MEPS beat, GAAPRevenue beat

Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.

Executive pay

as filed for fiscal 2025 · proxy filed Apr 28, 2026
ExecutiveSalaryStock awardsOtherTotal
Mr. ElshenawyChief Technology Officer$375K$57.2M$3.3M$60.9M
Mr. DudumChief Executive Officer and Chairman$495K$10.6M$11.8M$23.0M
Mr. OkupeChief Financial Officer$531K$7.5M$394K$8.4M
Mr. ChiChief Operating Officer (previously Chief Commercial Officer)$485K$6.9M$344K$7.7M
Ms. BoughtonChief Legal Officer$464K$4.0M$308K$4.8M

The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. 2 executives who have since left the company are named in that filing and not shown here. Read the filing

Institutional holders

13F positions as of Jun 30, 2026
HolderValueSharesShares vs prior qtr% of shares out
BlackRock, Inc.$995.2M28,703,514+9.0%12.39%
Vanguard Portfolio Management LLC$366.1M10,559,314+3.7%4.56%
Vanguard Capital Management LLC$330.8M9,541,384+2.2%4.12%
State Street Corp$282.4M8,145,699+9.2%3.51%
Morgan Stanley$248.0M7,152,498-19.5%3.09%
Divisadero Street Capital Management, LP$208.3M6,009,505+1179.1%2.59%
Geode Capital Management, LLC$197.0M5,681,832+9.3%2.45%
Goldman Sachs Group Inc$179.4M5,173,865+110.8%2.23%
JPMorgan Chase & Co.$159.5M4,766,781-9.0%2.06%
FMR LLC$149.9M4,323,292+4535.2%1.87%
Marshall Wace, LLP$146.2M4,217,767+482.4%1.82%
UBS Group AG$92.3M2,660,810-35.9%1.15%

A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.

Know when the next HIMS filing is reported.

GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.

Open-market insider trades

14 filings shown · newest filing first
InsiderActionSharesPriceValueTrade dateDelay
(business days)
Soleil BoughtonChief Legal OfficerSold · scheduled3,461$29.06$101KOct 14, 2026filed Oct 15, 20261d
Soleil BoughtonChief Legal OfficerSold · scheduled3,461$29.17$101KSep 30, 2026filed Oct 2, 20262d
Oluyemi OkupeChief Financial OfficerSold · scheduled2,000$29.70$59KOct 1, 2026filed Oct 2, 20261d
Oluyemi OkupeChief Financial OfficerSold · scheduled29,277$29.95$877KSep 22, 2026filed Sep 23, 20261d
Oluyemi OkupeChief Financial OfficerSold · scheduled12,313$28.82$355KSep 17, 2026filed Sep 18, 20261d
Mohamed ElshenawyCTOSold · scheduled7,954$28.39$226KSep 15, 2026filed Sep 17, 20262d
Michael ChiChief Operating OfficerSold · scheduled14,027$28.39$398KSep 15, 2026filed Sep 17, 20262d
Soleil BoughtonChief Legal OfficerSold · scheduled6,236$27.86$174KSep 16, 2026filed Sep 17, 20261d
Soleil BoughtonChief Legal OfficerSold · scheduled3,458$28.33$98KSep 2, 2026filed Sep 3, 20261d
Soleil BoughtonChief Legal OfficerSold · scheduled25,111$27.55$692KAug 19, 2026filed Aug 20, 20261d
Oluyemi OkupeChief Financial OfficerSold · scheduled4,938$29.99$148KAug 19, 2026filed Aug 20, 20261d
Deborah M. AutorChief Policy OfficerSold · scheduled16,773$27.85$467KAug 18, 2026filed Aug 20, 20262d
Oluyemi OkupeChief Financial OfficerSold · scheduled9,388$27.89$262KAug 17, 2026filed Aug 18, 20261d
Oluyemi OkupeChief Financial OfficerSold · scheduled55,383$35.09$1.9MJun 18, 2026filed Aug 18, 202641d

One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. Scheduled: set up in advance under a Rule 10b5-1 trading plan. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.

Other Form 4 activity (20)
InsiderEventSharesDate
Oluyemi OkupeChief Financial OfficerOption exercise14,000Sep 22, 2026
Andrew DudumChief Executive OfficerOther (see filing)977,566Aug 27, 2026
Andrew DudumChief Executive OfficerGift463,289Aug 25, 2026
Oluyemi OkupeChief Financial OfficerOption exercise4,938Aug 19, 2026
Deborah M. AutorChief Policy OfficerTax withholding16,147Aug 14, 2026
Deborah M. AutorChief Policy OfficerOption exercise32,920Aug 14, 2026
Oluyemi OkupeChief Financial OfficerOption exercise71,616Aug 14, 2026
Oluyemi OkupeChief Financial OfficerOption exercise9,388Aug 17, 2026
Oluyemi OkupeChief Financial OfficerTax withholding36,437Aug 14, 2026
Oluyemi OkupeChief Financial OfficerOption exercise71,616Aug 14, 2026
Michael ChiChief Operating OfficerOption exercise86,265Aug 14, 2026
Michael ChiChief Operating OfficerTax withholding47,702Aug 14, 2026
Michael ChiChief Operating OfficerOption exercise86,265Aug 14, 2026
Andrew DudumChief Executive OfficerOption exercise154,993Aug 14, 2026
Andrew DudumChief Executive OfficerTax withholding78,859Aug 14, 2026
Andrew DudumChief Executive OfficerOption exercise154,993Aug 14, 2026
Patrick Harrison CarrollChief Medical OfficerOption exercise25,927Aug 14, 2026
Patrick Harrison CarrollChief Medical OfficerTax withholding10,201Aug 14, 2026
Patrick Harrison CarrollChief Medical OfficerOption exercise26,187Aug 14, 2026
Kare SchultzDirectorOption exercise6,623Aug 14, 2026

Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.

Congress trades in HIMS

2 disclosures of 2 on record · median 37d of the 45 allowed

Since the trade: the stock's move from the trade date to the latest close we hold (figures as of Oct 24, 2026), not the member's result. Not investment advice.

MemberTypeActionAmount disclosedStock since the tradeTrade dateDisclosedDelay
Tony WiedStockPurchase$500,001 - $1,000,000+8.5%S&P 500 +10.2% · -1.7 pts vs S&P 500Feb 3, 2026Mar 9, 202634d
Lisa C. McClainSpouseStockPurchase$1,001 - $15,000-56.3%S&P 500 +20.4% · -76.7 pts vs S&P 500Aug 4, 2025Sep 12, 202539d

Since the trade is an estimate, set beside the S&P 500 over the same window, with the gap between the two in percentage points. The filing carries a band, not a fill, and a sale keeps the stock's sign, so a positive figure after a sale means the stock kept rising after it. An option row carries the underlying stock's move. A row marked n/a is one we hold no figure for.

Every Congress trade in HIMS, filterable by party, chamber, type and account.

Members of Congress reporting a position

1 member · estimate, as of Oct 22, 2026

1 member reports a position (estimated). The largest estimated position is in the $500,001 - $1,000,000 band.

MemberParty, chamberEstimated positionShare of their portfolio
Tony WiedRepublican · House$500,001 - $1,000,0003.6%

Estimate, as of Oct 22, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.

Questions

Are insiders buying or selling HIMS?

Across the 14 most recent open-market filings shown here, 0 were purchases and 14 were sales. 14 were scheduled in advance under a Rule 10b5-1 plan.

Which members of Congress have traded HIMS?

Tony Wied and Lisa C. McClain disclosed HIMS transactions in the filings shown here.

Which members of Congress hold HIMS?

1 member of Congress reports a position in HIMS in the estimate we hold as of Oct 22, 2026. The estimated position belongs to Tony Wied. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.

How quickly are HIMS trades disclosed?

Insider filings on this page reached the public a median of 1 business day after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows. Congressional disclosures took a median of 37 days, against the 45 the STOCK Act allows.

How to read a Form 4

A DECISION THE INSIDER MADE

POpen-market purchase. Bought with their own money at the market price.
SOpen-market sale. Sold on the market. A sale marked scheduled was set up in advance under a Rule 10b5-1 plan, often months before.

COMPENSATION PLUMBING

AStock award. Granted as pay, not bought.
MOption exercise. Converting options already held into shares.
FTax withholding. Shares handed back to the company to pay the tax on a grant.
GGift. Given away, with no money changing hands.

Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.

Data as of Oct 26, 2026.

Related companies

traded by the same members

See every company we track